Cassandra J Vandenberg Selected Research

Lymphoma (Lymphomas)

1/2020	Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
1/2018	Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
1/2016	RAG-induced DNA lesions activate proapoptotic BIM to suppress lymphomagenesis in p53-deficient mice.
3/2013	ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
6/2012	Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
12/2010	Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim.
10/2010	Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.
11/2008	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cassandra J Vandenberg Research Topics

Disease

13	Neoplasms (Cancer) 01/2022 - 07/2003
8	Lymphoma (Lymphomas) 01/2020 - 11/2008
3	Fanconi Anemia (Fanconi's Anemia) 11/2015 - 07/2003
2	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 01/2021
2	Multiple Myeloma 01/2020 - 08/2014
1	Carcinoma (Carcinomatosis) 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2016
1	Leukemia 01/2016
1	Plasmacytoma 08/2014
1	Lymphopenia (Lymphocytopenia) 08/2014
1	Melanoma (Melanoma, Malignant) 08/2014
1	Neoplasm Metastasis (Metastasis) 08/2014
1	Septic Shock (Toxic Shock Syndrome) 08/2014
1	Sepsis (Septicemia) 08/2014
1	Thrombocytopenia (Thrombopenia) 03/2013
1	Premature Menopause 11/2012
1	Carcinogenesis 08/2010
1	Chromosome Aberrations (Chromosome Abnormalities) 09/2005
1	Hypoxia (Hypoxemia) 08/2002

Drug/Important Bio-Agent (IBA)

5	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2008
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 01/2021
3	DNA (Deoxyribonucleic Acid)IBA 11/2015 - 09/2005
3	ABT-737IBA 03/2013 - 11/2006
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2010
2	Bcl-2-Like Protein 11IBA 01/2016 - 08/2014
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2010 - 11/2008
2	Fanconi Anemia Complementation Group D2 ProteinIBA 09/2005 - 07/2003
1	LCL161IBA 01/2022
1	PlatinumIBA 01/2022
1	olaparibIBA 01/2021
1	Bortezomib (Velcade)FDA Link 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020
1	Cyclin DIBA 08/2014
1	venetoclaxIBA 03/2013
1	Transcription Factors (Transcription Factor)IBA 11/2012
1	navitoclaxIBA 06/2012
1	GlucocorticoidsIBA 08/2010
1	Small Interfering RNA (siRNA)IBA 09/2005
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 09/2005
1	PolymersIBA 08/2002

Therapy/Procedure

7	Therapeutics 01/2020 - 11/2008
2	Drug Therapy (Chemotherapy) 01/2022 - 12/2010
1	Homologous Transplantation 08/2014
1	Transplantation 10/2010